Janssen
Guardant Health Liquid Biopsy CDx Gets Japanese Regulatory Approval for Janssen Lung Cancer Drug
Patients with inoperable or recurrent NSCLC and EGFR exon 20 insertion mutations may be eligible for Janssen Pharmaceutical's amivantamab-vmjw.
FDA Approves FoundationOne Liquid CDx to Select BRCA-Mutated mCRPC Patients for Janssen's Akeega
The FDA expanded the label to include the blood-based sequencing test as well as the tissue-based CDx, which was already approved to select patients for Akeega.
Illumina, Janssen to Collaborate on Molecular Residual Disease Liquid Biopsy Test
The new agreement is part of a long-term strategic collaboration the two firms signed in 2022 to develop precision medicines.
Roche, Janssen Expand Companion Diagnostic Collaboration
The new agreement allows the companies to collaborate with multiple technologies, including digital pathology and immunoassays.
Paige, Janssen Partner on Bladder Cancer Dx
Janssen's test relies on screening H&E-stained slides, followed by analysis with an internally developed algorithm.